Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued

Anti-diabetic oral GLP1 drug Rybelsus┬« (semaglutide) received FDA approval on September 20th and 70%-80% of patients are not coming from other injectables. GLP1 drug segment is growing led by the weekly injectable anti-diabetic drug Ozempic┬« (semaglutide) approved for CV risk reduction in the US. Revenue in US diabetes segment is flat due to declining revenue […]

AB InBev increases prices in South Korea and Brazil and sees volume decline

AB InBev issued a press release on their quarterly results before the market opened. The two most important headlines of the quarter were probably the listing of Budweiser APAC on the HKEx and implementation of price increases in South Korea and Brazil that drove volume declines. Whereas revenue and revenue per hectolitre were up, volume […]